目的 探討紅金消結(jié)片聯(lián)合醋酸戈舍瑞林緩釋植入劑治療子宮肌瘤的臨床療效。方法 選取2016年7月-2017年12月成都中醫(yī)藥大學(xué)附屬醫(yī)院婦科收治的子宮肌瘤患者74例為研究對(duì)象，采用隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各37例。對(duì)照組在月經(jīng)周期第1~7天內(nèi)經(jīng)腹部前壁皮下注射醋酸戈舍瑞林緩釋植入劑，3.6 mg/次，每隔28天注射1次。治療組在對(duì)照組治療的基礎(chǔ)上口服紅金消結(jié)片，4片/次，2次/d。兩組患者均連續(xù)治療3個(gè)月。觀察兩組的療效，比較兩組的血液流變學(xué)指標(biāo)、性激素水平、子宮體積和子宮肌瘤體積。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為78.38%、94.59%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血漿比黏度、纖維蛋白原、紅細(xì)胞聚集指數(shù)明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血液流變學(xué)指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清LH、FSH、P、E₂水平明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組性激素水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組子宮體積和子宮肌瘤體積明顯減小，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯小于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 紅金消結(jié)片聯(lián)合醋酸戈舍瑞林緩釋植入劑治療子宮肌瘤具有較好的臨床療效，可改善患者血液流變學(xué)，調(diào)節(jié)性激素水平，縮小患者子宮體積和子宮肌瘤體積，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Hongjin Xiaojie Tablets combined with Goserelin Acetate Sustained-Release Depot in treatment of uterine leiomyoma. Methods Patients (74 cases) with uterine leiomyoma in Teaching Hospital of Chengdu University of Traditional Chinese Medicine from July 2016 to December 2017 were randomly divided into control and treatment groups, and each group had 37 cases. Patients in the control group were sc administered with Goserelin Acetate Sustained-Release Depot through the anterior wall of the abdomen in the period of first to 7 d of the menstrual cycle, 3.6 mg/time, once every 28 days. Patients in the treatment group were po administered with Hongjin Xiaojie Tablets on the basis of the control group, 4 tablets/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and hemorheological indexes, sex hormone levels, uterine volume, and uterine leiomyoma volume in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.38% and 94.59%, respectively, and there was difference between two groups (P<0.05). After treatment, plasma viscosity, fibrinogen, and erythrocyte aggregation index in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the hemorheological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of LH, FSH, P, and E₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the sex hormone levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, uterine volume and uterine leiomyoma volume in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly smaller than those in the control group, with significant difference between two groups (P<0.05). Conclusion Hongjin Xiaojie Tablets combined with Goserelin Acetate Sustained-Release Depot has clinical curative effect in treatment of uterine leiomyoma, can improve hemorheology, regulate sex hormone levels, reduce uterine volume and uterine fibroid volume, with good safety, which has a certain clinical application value.